3 unknown. 3 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Unknown 3 |
| Phase 2 | 1 | Unknown 1 |
Follow Immunotherapy: new trials by email Literature Review of Immunotherapy trials Research Report on Immunotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Toripalimab Plus Radiotherapy for Elderly Esophageal Cancer Patients Treated With Non-chemotherapy Strategy Toripalimab, Tegafur, IMRT - Esophageal Cancer, Radiation Therapy | Phase 2 / Phase 3 | Unknown | Taizhou Hospital | 60 | 2022-07-01 | 2023-04-18 |
| PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine,Cytarabine, G-CSF for Refractory or Relapsed AML Visilizumab - Immunotherapy, Refractory Leukemia | Phase 3 | Unknown | The First Affiliated Hospital of Soochow University | 30 | 2021-05-01 | 2021-12-03 |
| Sintilimab Plus Bevacizumab as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Curative Resection Sintilimab, Bevacizumab - HCC, Adjuvant Therapy | Phase 3 | Unknown | Sun Yat-sen University | 246 | 2020-12-01 | 2020-12-23 |
Esophageal Neoplasms (1) · Leukemia (1) · Leukemia, Myeloid, Acute (1) · Recurrence (1)
Neoplasms (2) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Disease Attributes (1) · Esophageal Diseases (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1) · Head and Neck Neoplasms (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Leukemia, Myeloid (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Azacitidine (1) · Bevacizumab (1) · Cytarabine (1) · Homoharringtonine (1) · Radiation (1) · S 1 (combination) (1) · Tegafur (1) · sintilimab (1) · toripalimab (1) · visilizumab (1)
Sun Yat-sen University (1) · Taizhou Hospital (1) · The First Affiliated Hospital of Soochow University (1)
China (3)
Han Yue, Ph.D (1)